Mather Group’s CorMedix CRMD Stock Holding History

Mather Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-523	Closed	-$2.22K	–	1814
2024 Q2	$2.22K	Buy	+523	New	+$2.66K	﹤0.01%	1860

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mather Group's CRMD Position: Q3 2024 in Review

Mather Group sold out of CorMedix (CRMD) in Q3 2024, closing a stake of 523 shares — an estimated $2.22K sold.

Mather Group first reported a position in CRMD in Q2 2024 and held it in 1 quarter. The position peaked at $2.22K in Q2 2024. 102 funds tracked by Wall St. Rank hold CRMD as of Q3 2024.

Mather Group reported no remaining CorMedix position as of Q3 2024 after selling out during the quarter.
Mather Group sold 523 CorMedix shares in Q3 2024, an estimated $2.22K.
Mather Group first reported a position in CorMedix in Q2 2024 and held it in 1 quarter.
Mather Group's CorMedix position peaked at $2.22K in Q2 2024.
102 funds tracked by Wall St. Rank held CorMedix as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.